Company news
Faron Pharmaceuticals Oy (LSE:FARN) news
Faron Pharmaceuticals Oy news releases on 6ix. Latest, Apr 8, 2022: Managers' Transactions
Press releases — page 6
Managers' Transactions
April 8, 2022
Faron Closes HIBISCUS Trial
April 5, 2022
Faron´s Annual Report 2021 Published
March 25, 2022
Faron Publishes Research From INTEREST Trial
March 14, 2022
Presentation of Biomarker Data at AACR 2022
March 9, 2022
Notice of 2021 Full-Year Results and Annual Report
March 7, 2022
Faron presents at upcoming conferences
March 4, 2022
Faron Board Issues Warrants to IPF Partners
February 28, 2022
Faron Updates on Bexmarilimab Development Program
February 23, 2022
Faron Announces R&D Day
February 14, 2022
Scientific Reports Publishes INFORAAA Results
February 3, 2022
Holdings in Company
January 31, 2022
Faron at Proactive One2One Investor Forum
January 24, 2022
Faron to Present at Redeye Fight Cancer Seminar
January 17, 2022
Faron to Present at H.C. Wainwright BioConnect
January 5, 2022
Faron Appoints Marie-Louise Fjällskog as CMO
January 4, 2022
Faron's financial calendar for 2022
December 21, 2021
Faron Announces Topline MATINS Biomarker Analysis
December 9, 2021
Change in Faron's Management Team
December 1, 2021
Faron to Present at Jefferies Conference 2021
November 16, 2021
Faron awarded EUR 3.8 Million in Arbitration Case
November 9, 2021
Cellular and Molecular Life Sciences Publication
November 3, 2021
Registration of Placing Shares with Trade Register
October 1, 2021
Presentation of Updated MATINS Data at ESMO
September 17, 2021
Faron Announces Presentation at ESMO Congress
September 9, 2021
Half-Year Financials, January 1 - June 30 2021
August 26, 2021
First Patient Dosed in Phase II/III COVID-19 Trial
August 25, 2021
Notice of Half-Year Report
July 28, 2021
Faron to Host KOL Webinar on Clever-1 Receptor
July 12, 2021
Updated corporate presentation
June 22, 2021
Bexmarilimab granted key US patent
June 14, 2021
Bexmarilimab results published in CCR
June 3, 2021
Bexmarilimab shows promising anti-tumour activity
May 17, 2021
US rights to patent related to Traumakine
May 14, 2021
Result of AGM
April 23, 2021
Appointment of a Broker
March 29, 2021
Exercise of Options
March 25, 2021
Bexmarilimab (Clevegen) development update
March 22, 2021
Faron to Present at Oppenheimer Conference
March 11, 2021
Notice of Full-Year Results and Annual Report
February 25, 2021
Registration of Placing Shares
February 12, 2021
Update on TRAUMAKINE development
January 26, 2021
US Department of Defense to support TRAUMAKINE
January 18, 2021
Faron to Present at H.C. Wainwright
January 4, 2021
Faron's financial calendar for 2021
December 21, 2020
Presents at ESMO Immuno-Oncology Virtual Congress
December 10, 2020
To Participate in Upcoming Investor Conferences
November 23, 2020
Issue of Equity
November 20, 2020
First Results from WHO Solidarity Trial
October 16, 2020
Half-year Report
September 24, 2020